NCT04739826View on ClinicalTrials.gov

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

RecruitingOBSERVATIONAL
Enrollment

491

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2025

Conditions
CML, Chronic Phase; TKI
Interventions
DRUG

Flumatinib Mesylate

Flumatinib mesylate tablets 600mg qd

DRUG

Nilotinib Pill

Nilotinib Capsules 300mg bid

Trial Locations (1)

215000

RECRUITING

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER